Schrodinger Inc
NASDAQ:SDGR

Watchlist Manager
Schrodinger Inc Logo
Schrodinger Inc
NASDAQ:SDGR
Watchlist
Price: 21.46 USD -3.77% Market Closed
Market Cap: 1.6B USD
Have any thoughts about
Schrodinger Inc?
Write Note

Schrodinger Inc
Total Other Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Schrodinger Inc
Total Other Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Other Income CAGR 3Y CAGR 5Y CAGR 10Y
Schrodinger Inc
NASDAQ:SDGR
Total Other Income
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Veeva Systems Inc
NYSE:VEEV
Total Other Income
$199.9m
CAGR 3-Years
131%
CAGR 5-Years
53%
CAGR 10-Years
N/A
Inspire Medical Systems Inc
NYSE:INSP
Total Other Income
$196k
CAGR 3-Years
25%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Doximity Inc
NYSE:DOCS
Total Other Income
$62k
CAGR 3-Years
-75%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Omnicell Inc
NASDAQ:OMCL
Total Other Income
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
W
Waystar Holding Corp
NASDAQ:WAY
Total Other Income
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Schrodinger Inc
Glance View

Market Cap
1.6B USD
Industry
Health Care

Schrödinger, Inc. engages in the provision of chemical simulation software solutions to pharmaceutical industry. The company is headquartered in New York City, New York and currently employs 664 full-time employees. The company went IPO on 2020-02-06. The firm operates through two segments: Software and Drug Discovery. The Software segment is focused on licensing the Company’s software for molecular discovery. The Drug Discovery segment is focused on building a portfolio of preclinical and clinical drug programs, internally and through collaborations. The Company’s physics-based software platform enables discovery of molecules for drug development and materials applications. Its software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories. The Company’s pipeline includes CDC7, Wee1, MALT1, HIF-2 alpha and SOS1/KRAS. Its CDC7 is a small molecule inhibitor for treatment of solid and liquid tumors.

SDGR Intrinsic Value
14.9 USD
Overvaluation 31%
Intrinsic Value
Price

See Also

Back to Top